ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 732

Impact of Disease Course on Atherosclerotic Vascular Events, Osteoporosis and Osteonecrosis in Systemic Lupus Erythematosus

Konstantinos Tselios, Dafna D Gladman, Zahi Touma, Jiandong Su, Nicole Anderson and Murray Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Co-morbidities and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: We have shown that disease course over time in systemic lupus erythematosus (SLE) follows three distinct patterns (prolonged remission, relapsing remitting and persistently active). The impact of these patterns on the development of specific co-morbidities, such as atherosclerotic vascular events (AVEs), osteoporosis and osteonecrosis is not known. The aim of the present study was to assess the incidence of such co-morbidities in lupus patients in the long term.

Methods: The inception patients of our long-term longitudinal cohort (enrolled within 18 months of diagnosis), with at least 10 years of follow-up and no time interval >18 months between consecutive visits, were investigated. Prolonged remission (PR) was defined as a clinical SLEDAI-2K=0 [serology (anti-dsDNA antibodies and C3/C4 levels) excluded], achieved within five years since enrolment and maintained for ≥10 years after that. Relapsing-remitting (RR) pattern was defined based on ≥2 remission periods (one remission period equals two consecutive visits with a clinical SLEDAI-2K=0), while patients with no remission were categorized as persistently active (PA). Incidence rates for AVEs (angina, myocardial infarction, re-vascularization procedure, transient ischemic attack, stroke, peripheral vascular disease), osteoporosis (according to the WHO definition) and osteonecrosis (confirmed radiologically) were calculated at 10 years and at the end of follow-up (median 17.5 years).

Results: Of 267 patients who fulfilled the inclusion criteria, 27 (10.1%) achieved PR, 180 (67.4%) were RR and 25 (9.4%) PA. At enrollment, there were no significant differences in demographic, clinical, immunological and therapeutic characteristics among the groups. At 10 years, PA patients had received significantly more glucocorticosteroids [39.4±24.3g vs. 16.6±10.7g and 27.3±18.4g for the PR and RR groups, p<0.001]. The incidence rates of AVEs, osteoporosis and osteonecrosis at 10 years and for the entire duration of follow up are given in Table 1.

Table 1. Incidence rates (/100 patient-years) of AVEs, osteoporosis and osteonecrosis in all patients

 

PR (n=27)

RR (n=180)

PA (n=25)

p

Age at enrolment (mean±SD)

39.2 ± 14.1

35.2 ± 13.4

37 ± 13.9

0.142

At 10 years

AVEs (incidence, n, %)

0

2.7

4.3

0.002

Osteoporosis (incidence, n, %)

0.4

7.6

8.5

<0.001

Osteonecrosis (incidence, n, %)

8.5

10.3

12.4

0.142

At the end of follow-up

AVEs

0.75

6.4

8

<0.001

Osteoporosis

6.6

14.1

12.3

0.004

Osteonecrosis

10.7

16.5

18

0.001

P value from ANOVA (Analysis of Variance) for age and Cochran-Armitage trend test for all rates (between PR and the other groups). No differences were observed between the RR and PA groups.

Conclusion: Disease course had a significant impact on the rates of atherosclerotic vascular events, osteoporosis and osteonecrosis over time. Patients who had achieved prolonged remission developed significantly fewer such co-morbidities whereas the differences between the RR and PA patients were not statistically significant. 

 


Disclosure: K. Tselios, None; D. D. Gladman, None; Z. Touma, None; J. Su, None; N. Anderson, None; M. Urowitz, None.

To cite this abstract in AMA style:

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz M. Impact of Disease Course on Atherosclerotic Vascular Events, Osteoporosis and Osteonecrosis in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/impact-of-disease-course-on-atherosclerotic-vascular-events-osteoporosis-and-osteonecrosis-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-disease-course-on-atherosclerotic-vascular-events-osteoporosis-and-osteonecrosis-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology